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In myotonic dystrophy type 1 reduced
FDG-uptake on FDG-PET is most severe
in Brodmann area 8
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and Vincent Boudousq2
Abstract
Background: In myotonic dystrophy type 1 (DM1), only one FDG-PET study used statistical parametric mapping
(SPM) showing frontal reduced FDG-uptake. Our aim was to 1) identify the FDG-PET area with the most severe
reduced FDG-uptake using SPM8 in a larger group of patients 2) assess potential correlation between CTG-numbers
and FDG-PET.
Methods: FDG-PET was performed in 24 patients and compared to 24 controls. Pearson’s correlation was used to
analyse correlation.
Results: SPM8 revealed Brodmann area 8 as the area with the most severe reduced FDG-uptake. Weak, although
not statistically significant, correlation was observed between CTG-numbers and reduced FDG-uptake in Brodmann
area 8.
Conclusion: In DM1, Brodmann area 8 is the area with the most severe reduced FDG-uptake on FDG-PET.
Brodmann area 8 reduced FDG-uptake is correlated –although weakly- to CTG-repeat numbers.
Background
Myotonic dystrophy type 1 (DM1) is caused by an ex-
panded (CTG)n repeat within the noncoding 3’ untrans-
lated region of the myotonic dystrophy protein kinase gene.
Cerebral involvement, based on clinical, neuroimaging, and
neuropathological evidence, is frequent in DM1 [1–10].
Relatively few reports analysed 18 F-deoxy-glucose posi-
tron emission tomography (FDG-PET) in DM1 [1–4].
Only one large study used statistical parametric mapping
(SPM), showing bilateral frontotemporal reduced FDG-
uptake in the 17 studied patients [1]. In a subset of those
17 patients, a T1-weighted MRI-based partial volume
correction was applied. In these patients, bilateral frontal
reduced FDG-uptake was observed indicating that frontal
reduced FDG-uptake is probably an independent (i.e. not
associated with focal brain atrophy) phenomenon in DM1.
In their study, no significant correlation was found be-
tween FDG-PET metabolism and neuropsychological test
results. Correlation between the number of CTG repeats
and cerebral metabolism was not analysed directly in that
study. One FDG-PET study, using a kinetic modelling to
determine the local glucose consumption rate, found that
cerebral glucose reduced FDG-uptake was a triplet-size
dependent phenomenon. This method, however, requires
dynamic PET acquisitions and patient’s blood sampling
after 18 F-deoxyglucose injection.
Our aim was to analyse FDG-PET by SPM in a larger
group of DM1 patients in order to identify the area with
the most severe reduced FDG-uptake and to assess
potential correlation between CTG numbers and FDG-
uptake. Our study focused on FDG-PET and its relation
to CTG-repeats. We did not search for a relationship of




In our centre, 48 symptomatic and genetically proven
adult DM1 patients are in follow-up. Twenty four of
these patients accepted to undergo brain FDG-PET.
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Ethical approval was not needed for our study, since the
ethics committee of CHU Nîmes (France) considered
the FDG-PET scan as a standard procedure in DM1, if
informed consent was given by the patients. All partici-
pants gave their informed consent to publish indirect
identifiers such as age and gender. All patients gave their
informed consent. Patient’s characteristics are summa-
rized in Table 1. Characteristics of included patients
were: men/women ratio = 9/15, mean age of 47 years
(SD 12.5, range 26–74) at time of brain imaging, mean
age of symptom onset of 27 years (range 5–58, including
6 patients with symptom onset before 18 years of age
[range 5–14] and 18 patients with adult onset disease),
mean disease duration of 20 years (range 6–41), and
mean number of 799 CTG repeats (range 83–2000,
including 14 patients with CTG <1000 and 10 patients
with CTG of ≥1000). None of our patients had congeni-
tal DM1. Six out of 24 DM1 patients had associated
diabetes (including five patients treated with oral antidi-
abetic drugs only and one [patient nr 23] with insulin
treatment).
Analysis was done for the total of 24 DM1 patients
versus 24 controls. For SPM analysis, the control group
consisted of 24 subjects (including 10 women and 14
men; mean age 52, SD 10.5, range 32–70) who had nei-
ther a history of neurological and psychiatric illness nor
abnormalities on neurological examination. FDG-PET
scans in controls were performed for study reasons only.
FDG-PET
All brain FDG-PET scans were done on a PET-CT
GEMINI GXL (Philips Medical Systems). After fasting
for at least 6 h, blood glucose level was checked and less
than 160 mg/dl. The accepted glucose level of 160 mg/dl
in our study was relatively high (in contrast with the
more commonly used cutoff of 120 mg/dl) because of
frequently associated diabetes in DM1 patients. Mean
glucose level in our DM1 patients was 103 mg/dl (range
80–159, of whom only 3 patients [i.e. patient nr 3, 8,
and 15] had blood glucose levels between 120 and
160 mg/dl). Patients were positioned comfortably in a
quiet, dimly lit room before FDG administration and
during the uptake phase of FDG (at least 20 min). They
received intravenous injection of 185 to 250 MBq (5 to
6.7 mCi: according to the weight) of 18F-FDG by a
canula inserted 10 min before. They were instructed not
Table 1 Patient characteristics
Patient Number Sex Age symptom onset Age at FDG-PET CTG expansion Diabetes (glucose level)
1 F 58 (late onset) 64 83 No (<120 mg/dl)
2 M 35 (late onset) 74 100 No (<120 mg/dl)
3 F 45 (late onset) 64 150 Yes (120–160 mg/dl)
4 F 32 (late onset) 46 176 No (<120 mg/dl)
5 F 25 (late onset) 41 230 No (<120 mg/dl)
6 F 30 (late onset) 49 330 No (<120 mg/dl)
7 M 26 (late onset) 36 400 No (<120 mg/dl)
8 M 30 (late onset) 50 400 Yes (120–160 mg/dl)
9 F 19 (late onset) 26 400 No (<120 mg/dl)
10 F 30 (late onset) 49 400 No (<120 mg/dl)
11 M 40 (late onset) 58 430 No (<120 mg/dl)
12 F 14 (early onset) 34 660 No (<120 mg/dl)
13 F 13 (early onset) 27 660 No (<120 mg/dl)
14 F 14 (early onset) 31 670 No (<120 mg/dl)
15 F 28 (late onset) 54 850 Yes (120–160 mg/dl)
16 F 39 (late onset) 47 1000 No (<120 mg/dl)
17 M 40 (late onset) 51 1168 Yes (<120 mg/dl)
18 M 24 (late onset) 44 1300 No (<120 mg/dl)c
19 F 28 (late onset) 50 1400 No (<120 mg/dl)
20 M 29 (late onset) 46 1500 No (<120 mg/dl)
21 F 38 (late onset) 58 1560 No (<120 mg/dl)
22 M 5 (early onset) 41 1600 No (<120 mg/dl)
23 M 14 (early onset) 55 1700 Yes (<120 mg/dl)
24 F 6 (early onset) 26 2000 Yes (<120 mg/dl)
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to speak, read or be otherwise active. For imaging,
patients were in supine position and their head immobi-
lized in a masthead. Imaging started with a CT surview
(view angle 90, Kv 120, 30 mAs), then transmission CT
scan for attenuation correction was done (120 KV, Mas/
slice 200, Pitch 0.563, Rotation 1.5, thickness 3 mm,
filter UB, collimation 16 × 1.5, FOV 600); static emission
scan started 30 min after injection, in 3-D mode for
20 min, axial field of view 180 mm, 256 × 256 matrix,
voxel size 2 mm3. PET raw data were corrected for at-
tenuation, random effects and scatter, the reconstruction
was then done with a three dimensional row-action
maximum likehood algorithm LOR-RAMLA resulted in
90 transaxial slices.
Statistical analysis were done using SPM8 software
(Wellcome Department of Imaging Neuroscience,
London; http://www.fil.ion.ucl.ac.uk/spm) running on
Matlab R2012b version (The Mathworks Inc., USA)
running on a Windows XP. Images were realigned and
spatially normalized into the MNI (Montreal Neuro-
logical Institute, McGill University, Montreal, QC,
Canada) standard template given by SPM software using
affine and non-linear transformation. Images were re-
formatted to a final voxel size of 2 × 2 × 2 mm and
smoothed using an isotropic Gaussian kernel of 12 ×
12 × 12 mm FWHM. A global normalization for voxel
count was performed using a proportional scaling.
Statistical comparisons between groups were performed
on a voxel-by-voxel basis t statistics, using "two-sample
t-test" design of the SPM8 generating SPM (t) maps. We
investigated brain areas with reduced FDG-uptake, a
stringent level of significance of p < 0.05 corrected for
multiple comparisons (SPM family wise error—FWE)
was adopted with an extent threshold of 100 voxels. For
visualization the significant voxels were projected onto
the 3D rendered brain or a standard MRI template
allowing anatomic identification. A MNI to Talairach
coordinates conversion was done using Yale Bioimage
Suite software (http://www.bioimagesuite.org). On sub-
sequent analyses by lowering p-values successively, we
searched for the brain area with the most severe reduced
FDG-uptake.
Statistical analyses
Pearson product–moment correlation coefficient was
used to analyse potential correlation between the number
of CTG repeats and reduced FDG-uptake (by using Z-
scores of individual patients). We also compared (using
Student’s t-test) uptake between the group of patients with
CTG <1000 versus CTG ≥1000 and between the group of
patients with early, childhood (age <18) onset versus late,
adult (age >18) onset.
The 24 controls were part of a larger control group of
35 cases (age range 32–86). Only the youngest 24 con-
trols were selected in order to avoid possible age-related
bias. Difference in age between the 24 DM1 patients and
the 24 controls were analyzed by a 2-sample t-test.
In all analyses, when comparing (sub)groups, a thresh-
old of p < 0.05 was used to differentiate significant from
non-significant differences.
Results
The age difference between DM1 patients (mean age 47)
and controls (mean age 52) was statistically not
significant.
SPM8 analysis of cerebral FDG-PET metabolism in
our 24 DM1 patients revealed significant bilateral sym-
metrical reduced FDG-uptake in the lateral part of the
frontal lobes (Fig. 1). The area with the most severe re-
duced FDG-uptake was Brodmann area 8, associated
with slight involvement of Brodmann area 9 on the right
side. Deep grey matter structures did not show reduced
metabolism. When using an extent threshold of 50 vox-
els, FDG-PET showed no supplementary areas with
reduced FDG-uptake compared to when using an extent
threshold of 100 voxels.
The number of CTG repeats was not correlated
with FDG-PET metabolism neither for the entire
brain nor for the frontal lobes (considered as a
whole). Positive -but statistically not significant- cor-
relation was found between the CTG numbers and the
metabolism in Brodmann area 8 (especially for the right
side, rho = −0.36; rho = −0.22 for the left side).
When comparing patients with <1000 CTG and ≥1000
CTG, patients with ≥1000 CTG showed lower Z-
Fig. 1 Compared with controls, SPM analysis (a, sagittal view; b, coronal view, and c, axial view) of our 24 DM1 patients showing bilateral
reduced FDG-uptake in the lateral part of the frontal lobes, with Brodmann area 8 as the zone with the most severe reduced FDG-uptake
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scores in the Brodmann area 8 (median −0.69 for the
right and −0.75 for the left Brodmann area 8) than
patients with <1000 CTG (median −0.46 for the right
and −0.58 for the left Brodmann area 8) although not
statistically significant (p = 0.28 and p = 0.52 for the
right and the left side respectively).
When comparing patient with early (childhood) and
late (adult) onset DM1, early onset patients showed
lower Z-scores (median −0.81 for the right and −0.78 for
the left Brodmann area 8) than patients with late onset
(median −0.53 for the right and −0.72 for the left Brod-
mann area 8), without statistically significance (p = 0.085
and p = 0.5 for the right and the left side respectively).
SPM analyses did not show significant differences
between diabetic (n = 6) and non-diabetic (n = 18) DM1
patients or between patients with blood glucose levels
<120 mg/dl (n = 21) and patients with blood glucose
levels between 120 and 160 mg/dl (n = 3).
Discussion
To the best of our knowledge, this is the largest study
analysing FDG-PET by SPM in DM1. We found lateral
frontal reduced FDG-uptake as predominant FDG-PET
pattern, confirming the data of the only existing study
using SPM. The zone with reduced FDG-uptake in our
study (although not partial volume corrected) was more
restricted than the reported area in the earlier study
(using partial volume correction). This might be related
to the higher number of patients analyzed and/or due
the lack of partial volume correction in our study. The
area with the most severe reduced FDG-uptake in our
study was identified as Brodmann area 8, associated with
slight involvement of the right Brodmann area 9. Al-
though statistically not significant, reduced FDG-uptake
was more severe in these brain areas in patients with
early, childhood (opposed to late, adult) onset and in
patients with ≥1000 (opposed to <1000) CTG.
CTG numbers typically differ between different tissues
(e.g. between blood and brain tissue). Therefore, the
CTG repeat number obtained by blood sample (like in
our study) does not necessarily reflect the number of
CTG repeats in the brain (and the brain abnormalities
found on FDG-PET possibly related to these repeat num-
bers). The absence of weak relationship between these
blood CTG repeat numbers and (clinical or radiological)
brain abnormalities in the earlier reports and our study
might be explained in part by this phenomenon.
Interestingly, the area with the most severe reduced
FDG-uptake in our DM1 patients was Brodmann area 8,
an area involved in (or at least very near to zones impli-
cated in) eye movement control (Brodmann area 8A
corresponding to the frontal eye field and area 8B corre-
sponding to the premotor ear-eye field, although the
exact localisation of these fields are still under debate).
A multitude of oculomotor abnormalities have been
reported in DM1 [11–13]. Some of these oculomotor ab-
normalities are thought to be due to oculomotor muscle
dysfunction (weakness and/or myotonia) whereas other
abnormalities suggest brain dysfunction. Studies are
needed to analyse the relationship between oculomotor
deficits (especially those related to dysfunction of the
frontal eye field and the premotor ear-eye field) and
FDG-PET metabolism.
Conclusion
In DM1, Brodmann area 8 is the area with the most
severe reduced FDG-uptake on FDG-PET. Brodmann
area 8 reduced FDG-uptake is weakly correlated to
CTG-repeat numbers.
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